Compare Ally Financial Inc (ALLY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Sanofi SA — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.37B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 7.8× Ally Financial Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ALLY | SNY | |
|---|---|---|
Market Cap | $13.37B | $104.30B |
Sector | Financials | Health |
52-Week High | $47.25 | $52.34 |
52-Week Low | $35.96 | $41.33 |
Dividend Yield | 2.73% | 5.55% |
Enterprise Value | — | $124.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.79, showing modest daily gains of 0.16%. The stock presents a compelling valuation with a P/E of 10.34 and P/B of 0.99, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations despite revenue growth, while technical indicators show bearish momentum with the stock trading near key support levels. The company maintains strong institutional support with 68% analyst buy ratings and recently declared a $0.30 dividend.
Ally offers value investment potential with attractive valuation metrics and solid dividend yield, though near-term headwinds include recent earnings miss and bearish technical signals. The auto finance business faces credit risk concerns amid economic uncertainty, but long-term digital banking leadership and improving margins provide growth catalysts. Upside potential exists if the company can maintain credit quality while expanding its digital banking footprint.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
